The combination of Dapagliflozin therapy with dietary carbohydrate restriction for 12 months in patients with T2D and class 3 obesity resulted in a significant and substantial reduction of body weight, fat mass and serum leptin, but without any discernible compensatory changes in metabolic rate or appetite. This evidence concerns the gene LEP and obesity due to melanocortin 4 receptor deficiency.